Equities analysts predict that Atreca (NASDAQ:BCEL) will post earnings of ($0.74) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Atreca’s earnings, with the lowest EPS estimate coming in at ($0.80) and the highest estimate coming in at ($0.67). Atreca reported earnings of ($3.67) per share during the same quarter last year, which indicates a positive year over year growth rate of 79.8%. The firm is scheduled to issue its next earnings report on Tuesday, August 11th.
According to Zacks, analysts expect that Atreca will report full year earnings of ($3.07) per share for the current year, with EPS estimates ranging from ($3.47) to ($2.77). For the next year, analysts anticipate that the company will post earnings of ($2.96) per share, with EPS estimates ranging from ($3.61) to ($1.91). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Atreca.
Atreca (NASDAQ:BCEL) last posted its earnings results on Thursday, May 14th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.73).
BCEL has been the topic of a number of recent analyst reports. ValuEngine upgraded shares of Atreca from a “hold” rating to a “buy” rating in a research note on Thursday, March 5th. BidaskClub upgraded shares of Atreca from a “hold” rating to a “buy” rating in a research note on Thursday, June 25th. Cowen restated a “buy” rating on shares of Atreca in a research note on Wednesday, June 17th. Robert W. Baird initiated coverage on shares of Atreca in a research note on Wednesday, April 15th. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Atreca in a research note on Tuesday, June 16th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $25.70.
In related news, Director William Hewitt Robinson sold 10,245 shares of Atreca stock in a transaction dated Friday, June 19th. The stock was sold at an average price of $20.03, for a total value of $205,207.35. Following the transaction, the director now owns 414,616 shares of the company’s stock, valued at approximately $8,304,758.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tito Serafini sold 4,604 shares of Atreca stock in a transaction dated Friday, June 19th. The stock was sold at an average price of $20.03, for a total value of $92,218.12. Following the completion of the transaction, the insider now directly owns 3,655 shares in the company, valued at approximately $73,209.65. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 107,200 shares of company stock worth $1,879,286. 9.90% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp increased its stake in Atreca by 142.2% in the 1st quarter. State Street Corp now owns 282,909 shares of the company’s stock worth $4,682,000 after purchasing an additional 166,100 shares in the last quarter. Jane Street Group LLC purchased a new position in Atreca during the 1st quarter valued at about $237,000. Invesco Ltd. purchased a new position in Atreca during the 1st quarter valued at about $597,000. Wells Fargo & Company MN grew its stake in Atreca by 32.2% during the 1st quarter. Wells Fargo & Company MN now owns 23,486 shares of the company’s stock valued at $389,000 after acquiring an additional 5,723 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Atreca by 89.6% during the 1st quarter. Geode Capital Management LLC now owns 171,116 shares of the company’s stock valued at $2,831,000 after acquiring an additional 80,874 shares in the last quarter. 62.14% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ BCEL traded up $0.51 during midday trading on Tuesday, reaching $21.13. 4,746 shares of the company traded hands, compared to its average volume of 246,997. Atreca has a 52 week low of $9.51 and a 52 week high of $29.35. The stock has a 50-day moving average price of $18.79 and a 200 day moving average price of $17.62. The company has a market cap of $584.37 million and a price-to-earnings ratio of -3.71.
Atreca Company Profile
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Recommended Story: What is the S&P/ASX 200 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.